

Aleksandra Antovic

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5947042/publications.pdf>

Version: 2024-02-01

66
papers

909
citations

471509

17
h-index

526287

27
g-index

66
all docs

66
docs citations

66
times ranked

1052
citing authors

#	ARTICLE	IF	CITATIONS
1	A Simple and Rapid Laboratory Method for Determination of Haemostasis Potential in Plasma. <i>Thrombosis Research</i> , 2001, 103, 355-361.	1.7	122
2	The Overall Hemostasis Potential: A Laboratory Tool for the Investigation of Global Hemostasis. <i>Seminars in Thrombosis and Hemostasis</i> , 2010, 36, 772-779.	2.7	46
3	Studies of microparticles in patients with the antiphospholipid syndrome (APS). <i>Lupus</i> , 2012, 21, 802-805.	1.6	46
4	Obstetric antiphospholipid syndrome. <i>Lupus Science and Medicine</i> , 2018, 5, e000197.	2.7	42
5	Marked increase of fibrin gel permeability with very low dose ASA treatment. <i>Thrombosis Research</i> , 2005, 116, 509-517.	1.7	39
6	Effects of direct oral anticoagulants on lupus anticoagulant assays in a real-life setting. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1700-1704.	3.4	37
7	Hemostasis in Off-Pump Compared to On-Pump Coronary Artery Bypass Grafting: A Prospective, Randomized Study. <i>Annals of Thoracic Surgery</i> , 2005, 80, 586-593.	1.3	34
8	Modifications of flow measurement to determine fibrin gel permeability and the preliminary use in research and clinical materials. <i>Blood Coagulation and Fibrinolysis</i> , 2005, 16, 61-67.	1.0	31
9	Evidence of hypercoagulability and inflammation in young patients long after acute cerebral ischaemia. <i>Thrombosis Research</i> , 2007, 120, 39-46.	1.7	29
10	Does Thrombin Activatable Fibrinolysis Inhibitor (TAFI) Contribute to Impairment of Fibrinolysis in Patients with Preeclampsia and/or Intrauterine Fetal Growth Retardation?. <i>Thrombosis and Haemostasis</i> , 2002, 88, 644-647.	3.4	27
11	The antiphospholipid syndrome “ often overlooked cause of vascular occlusions?. <i>Journal of Internal Medicine</i> , 2020, 287, 349-372.	6.0	27
12	Increased hemostasis potential persists in women with previous thromboembolism with or without APC resistance. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 2531-2535.	3.8	24
13	Studies of fibrin formation and fibrinolytic function in patients with the antiphospholipid syndrome. <i>Thrombosis Research</i> , 2014, 133, 936-944.	1.7	23
14	The assay of overall haemostasis potential used to monitor the low molecular mass (weight) heparin, dalteparin, treatment in pregnant women with previous thromboembolism. <i>Blood Coagulation and Fibrinolysis</i> , 2002, 13, 181-186.	1.0	22
15	High-Dose Aspirin Is Required to Influence Plasma Fibrin Network Structure in Patients With Type 1 Diabetes. <i>Diabetes Care</i> , 2012, 35, 404-408.	8.6	20
16	Does recombinant factor VIIa, apart from overall hemostasis, regulate TAFI dependent fibrinolysis? In vitro analysis using overall hemostasis potential (OHP) assay. <i>Thrombosis and Haemostasis</i> , 2003, 90, 620-627.	3.4	19
17	Screening Haemostasis “ Looking for Global Assays: The Overall Haemostasis Potential (OHP) Method “ A Possible Tool for Laboratory Investigation of Global Haemostasis in Both Hypo- and Hypercoagulable Conditions. <i>Current Vascular Pharmacology</i> , 2008, 6, 173-185.	1.7	19
18	Identifying hypocoagulable states with a modified global assay of overall haemostasis potential in plasma. <i>Blood Coagulation and Fibrinolysis</i> , 2005, 16, 585-596.	1.0	17

#	ARTICLE	IF	CITATIONS
19	Two global haemostatic assays as additional tools to monitor treatment in cases of haemophilia A. <i>Thrombosis and Haemostasis</i> , 2012, 108, 21-31.	3.4	17
20	Improvement of fibrin clot structure after factor VIII injection in haemophilia A patients treated on demand. <i>Thrombosis and Haemostasis</i> , 2014, 111, 656-661.	3.4	17
21	Comparison of standard fibrinogen measurement methods with fibrin clot firmness assessed by thromboelastometry in patients with cirrhosis. <i>Thrombosis Research</i> , 2015, 135, 1124-1130.	1.7	16
22	Evaluation of global haemostatic assays and fibrin structure in patients with pre-eclampsia. <i>International Journal of Laboratory Hematology</i> , 2020, 42, 322-330.	1.3	15
23	The expression of microvesicles in the blood of patients with Graves' disease and its relationship to treatment. <i>Clinical Endocrinology</i> , 2016, 84, 729-735.	2.4	14
24	Thrombin activatable fibrinolysis inhibitor (TAFI) – A possible link between coagulation and complement activation in the antiphospholipid syndrome (APS). <i>Thrombosis Research</i> , 2017, 158, 168-173.	1.7	14
25	Venous Thromboembolic Events in Idiopathic Inflammatory Myopathy: Occurrence and Relation to Disease Onset. <i>Arthritis Care and Research</i> , 2018, 70, 1849-1855.	3.4	14
26	Obstetric outcomes in patients with primary thrombotic and obstetric antiphospholipid syndrome and its relation to the antiphospholipid antibody profile. <i>Lupus</i> , 2019, 28, 868-877.	1.6	14
27	Microparticles Expressing Myeloperoxidase and Complement C3a and C5a as Markers of Renal Involvement in Antineutrophil Cytoplasmic Antibody-associated Vasculitis. <i>Journal of Rheumatology</i> , 2020, 47, 714-721.	2.0	14
28	QSPR in forensic analysis – The prediction of retention time of pesticide residues based on the Monte Carlo method. <i>Talanta</i> , 2018, 178, 656-662.	5.5	13
29	Primary pericardial mesothelioma presenting as constrictive pericarditis. <i>Archive of Oncology</i> , 2005, 13, 150-152.	0.2	12
30	Phosphatidylserine positive microparticles improve hemostasis in in-vitro hemophilia A plasma models. <i>Scientific Reports</i> , 2020, 10, 7871.	3.3	11
31	Assessment of hemostatic disturbances in women with established rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2019, 38, 3005-3014.	2.2	10
32	Microparticles expressing myeloperoxidase as potential biomarkers in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV). <i>Journal of Molecular Medicine</i> , 2020, 98, 1279-1286.	3.9	10
33	Overall hemostatic potential (OHP) assay-a possible tool for determination of prothrombotic pattern in FXII deficiency. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 2058-2060.	3.8	9
34	Venous thromboembolism in anti-neutrophil cytoplasmic antibody-associated vasculitis: an underlying prothrombotic condition?. <i>Rheumatology Advances in Practice</i> , 2020, 4, rkaa056.	0.7	9
35	Impaired Fibrinolysis in the Antiphospholipid Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 506-511.	2.7	9
36	Immunohistochemical distribution of Ki67 in epidermis of thick glabrous skin of human digits. <i>Archives of Dermatological Research</i> , 2018, 310, 85-93.	1.9	7

#	ARTICLE	IF	CITATIONS
37	Synergistic Effect of Bypassing Agents and Sequence Identical Analogue of Emicizumab and Fibrin Clot Structure in the In Vitro Model of Hemophilia A. <i>TH Open</i> , 2020, 04, e94-e103.	1.4	6
38	The Silence Speaks, but We Do Not Listen: Synonymous c.1824C>T Gene Variant in the Last Exon of the Prothrombin Gene as a New Prothrombotic Risk Factor. <i>Clinical Chemistry</i> , 2020, 66, 379-389.	3.2	6
39	The Influence of Menopause and Inflammation on Redox Status and Bone Mineral Density in Patients with Rheumatoid Arthritis. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-12.	4.0	6
40	Increased Expression of Extracellular Vesicles Is Associated With the Procoagulant State in Patients With Established Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , 2021, 12, 718845.	4.8	6
41	On-demand but not prophylactic treatment with FVIII concentrate increase thrombin activatable fibrinolysis inhibitor activation in severe haemophilia A patients. <i>International Journal of Laboratory Hematology</i> , 2012, 34, 35-40.	1.3	5
42	Phosphatidylserine Exposing Extracellular Vesicles in Pre-eclamptic Patients. <i>Frontiers in Medicine</i> , 2021, 8, 761453.	2.6	5
43	Pentraxin-3 – a potential biomarker in ANCA-associated vasculitis. <i>Scandinavian Journal of Rheumatology</i> , 2023, 52, 293-301.	1.1	5
44	The Complex Relationship between C4b-Binding Protein, Warfarin, and Antiphospholipid Antibodies. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1299-1309.	3.4	3
45	Evaluation of risk factors and biomarkers related to arterial and venous thrombotic events in idiopathic inflammatory myopathies. <i>Scandinavian Journal of Rheumatology</i> , 2021, 50, 390-397.	1.1	3
46	Pancreatic Polypeptide-Secreting Tumour of the Proximal Pancreas (PPoma) – Ultra Rare Pancreatic Tumour: Clinically Malign, Histologically Benign. <i>Medicina (Lithuania)</i> , 2019, 55, 523.	2.0	2
47	Diagnostic Accuracy in Acute Venous Thromboembolism: Comparing D-Dimer, Thrombin Generation, Overall Hemostatic Potential, and Fibrin Monomers. <i>TH Open</i> , 2020, 04, e178-e188.	1.4	2
48	Effects of rivaroxaban and dabigatran on global hemostasis in patients with atrial fibrillation. <i>Blood Coagulation and Fibrinolysis</i> , 2020, 31, 243-252.	1.0	2
49	THU0134 – Ultrasound detected tenosynovitis predicts arthritis onset in individuals at risk of developing rheumatoid arthritis. , 2018, , .		2
50	SAT0584 – SPECIFIC ACPA REACTIVITIES AND INFLAMMATORY BIOMARKERS ALONG WITH ULTRASOUND TENOSYNOVITIS ARE ASSOCIATED WITH ARTHRITIS ONSET IN A POPULATION AT RISK FOR RHEUMATOID ARTHRITIS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1251.2-1251.	0.9	2
51	Impaired Fibrinolysis Is Linked With Digital Vasculopathy and Onset of New Digital Ulcers in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2022, , jrheum.210931.	2.0	2
52	SAT0004 – Increased Levels of Thrombin Activatable Fibrinolysis Inhibitor - TAFI Correlate with Complement Activation in Patients with the Antiphospholipid Syndrome. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 591.1-591.	0.9	1
53	Morphometric analysis of the epineurial and endoneurial blood vessels of the human sciatic nerve in relation to aging. <i>Tissue and Cell</i> , 2020, 66, 101389.	2.2	1
54	Redox Status in Women with Rheumatoid Arthritis. <i>Serbian Journal of Experimental and Clinical Research</i> , 2021, 22, 29-36.	0.1	1

#	ARTICLE	IF	CITATIONS
55	Adrenal apoplexy caused by fulminant sepsis in 20-year-old healthy male?: case report. Open Medicine (Poland), 2013, 8, 485-488.	1.3	0
56	FRI0593â€¦Effects of New (Direct) Oral Anticoagulants on Lupus Anticoagulant Assays. Annals of the Rheumatic Diseases, 2015, 74, 642.3-643.	0.9	0
57	A5.8â€¦The use of cardiovascular risk module within the swedish rheumatology quality registry (SRQ) helps in daily clinical praxis. Annals of the Rheumatic Diseases, 2015, 74, A50.1-A50.	0.9	0
58	AB0647â€¦ASSOCIATION OF VASCULAR BIOMARKERS WITH SYSTEMIC SCLEROSIS CLINICAL FEATURES AND NAILFOLD VIDEOCAPILLAROSCOPY ALTERATIONS-CROSS SECTIONAL STUDY. , 2019, , .		0
59	O32â€¦Skin proteome investigation in cutaneous lupus erythematosus (CLE) reveals novel unique disease pathways. , 2020, , .		0
60	Morphometric analysis of the human endoneurial extracellular matrix components during aging. Archives of Biological Sciences, 2021, 73, 103-110.	0.5	0
61	POS1230â€¦OUTCOME FOLLOWING COVID-19 INFECTION IN ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA)-ASSOCIATED VASCULITIS. Annals of the Rheumatic Diseases, 2021, 80, 898.2-898.	0.9	0
62	POS0874â€¦CLOT LYSIS TIME PREDICTS RECURRENT DIGITAL ULCERS IN SYSTEMIC SCLEROSIS AFTER ONE YEAR OF FOLLOW-UP: A NESTED CASE-CONTROL STUDY. Annals of the Rheumatic Diseases, 2021, 80, 693.1-693.	0.9	0
63	AB0345â€¦The Use of Cardiovascular Risk Module Within the Swedish Rheumatology Quality Registry (SRQ) Helps in Daily Clinical Praxis. Annals of the Rheumatic Diseases, 2015, 74, 1009.1-1009.	0.9	0
64	OP0052â€¦Microparticles as potential biomarkers of disease activity in anti-neutrophil cytoplasmic antibody â€œ associated vasculitis. , 2018, , .		0
65	THU0224â€¦SKIN PROTEOME INVESTIGATION IN CUTANEOUS LUPUS ERYTHEMATOSUS (CLE) REVEALS NOVEL UNIQUE DISEASE PATHWAYS. Annals of the Rheumatic Diseases, 2020, 79, 339.2-339.	0.9	0
66	FRI0232â€¦ALTERED FIBRIN CLOT PROPERTIES IN PATIENTS WITH SYSTEMIC SCLEROSIS. Annals of the Rheumatic Diseases, 2020, 79, 699.2-700.	0.9	0